Palisade Bio Wins Health Canada Clearance for Phase 2 Ulcerative Colitis Trial of PALI-2108

Palisade Bio (PALI) said Health Canada has cleared its Clinical Trial Application for ASCENTRA-UC, a global Phase 2 study evaluating PALI-2108 in patients with moderately to severely active ulcerative colitis. The clearance allows the company to proceed with the trial, which targets an inflammatory bowel disease population with limited treatment options. No financial terms or enrollment timelines were disclosed. The announcement, dated September 23, 2026, marks a regulatory milestone for Palisade's PALI-2108 development program. Shares trade under the ticker PALI.